Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity
Compose a Response to This Article
Other responses
No responses have been published for this article.